35889-03-3

Basic information

• Product Name: Benzeneacetic acid, 4-(phenylmethyl)-
• CAS NO: 35889-03-3
• Molecular Formula: C15H14O2
• Molecular Weight: 226.275
• Mol File: 35889-03-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzeneacetic acid, 4-(phenylmethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzeneacetic acid, 4-(phenylmethyl)-(35889-03-3)
• EPA Substance Registry System: Benzeneacetic acid, 4-(phenylmethyl)-(35889-03-3)

Safety Data

• Hazardous Substances Data: 35889-03-3(Hazardous Substances Data)

Upstream product

• 26077-80-5 (4-benzoylphenyl)acetic acid 
• 134-84-9 4-Methylbenzophenone 
• 21192-61-0 2-(4-benzoylphenyl)acetonitrile 
• 32752-54-8 4-(bromomethyl)benzophenone 
• 101430-99-3 1-(4-benzyl-phenyl)-propan-2-ol 
• 101096-72-4 4-benzyl-1-cyanomethylbenzene 

Downstream Products

• 1356067-55-4 (±)-tetrahydro-2H-pyran-2-ylmethyl (4-benzylphenyl)acetate 
• 1356067-69-0 2-(benzyloxy)-1-[(benzyloxy)methyl]ethyl 2-(4-benzylphenyl)acetate 
• 1356067-64-5 2-hydroxy-1-(hydroxymethyl)ethyl 2-(4-benzylphenyl)acetate 
• 1356067-51-0 (+/-)-oxiran-2-ylmethyl 2-(4-benzylphenyl)acetate 
• 1356067-61-2 (2R)-(-)-oxiran-2-ylmethyl 2-(4-benzylphenyl)acetate 
• 1356067-62-3 (2S)-(+)-oxiran-2-ylmethyl 2-(4-benzylphenyl)acetate 
• 98901-18-9 N-tert-butyl-2-(p-benzylphenyl)acetamide 
• 18908-75-3 (4-benzyl-phenyl)-acetic acid ethyl ester 
• 1054796-95-0 (4S,5R,6R)-5-Acetylamino-6-{[2-(4-benzyl-phenyl)-ethyl]-propyl-carbamoyl}-4-tert-butoxycarbonylamino-5,6-dihydro-4H-pyran-2-carboxylic acid benzhydryl ester 
• 1027578-81-9 [2-(4-Benzyl-phenyl)-ethyl]-propyl-amine 
• 98901-20-3 (4-Benzyl-phenyl)-acetyl chloride 
• 1449214-07-6 C₅₄H₅₄O₆ 

Relevant articles and documents

A reversible and selective inhibitor of monoacylglycerol lipase ameliorates multiple sclerosis

Monoacylglycerol lipase (MAGL) is the enzyme responsible for the inactivation of the endocannabinoid 2-arachidonoylglycerol (2-AG). MAGL inhibitors show analgesic and tissue-protecting effects in several disease models. However, the few efficient and selective MAGL inhibitors described to date block the enzyme irreversibly, and this can lead to pharmacological tolerance. Hence, additional classes of MAGL inhibitors are needed to validate this enzyme as a therapeutic target. Here we report a potent, selective, and reversible MAGL inhibitor (IC50 = 0.18 mm) which is active in vivo and ameliorates the clinical progression of a multiple sclerosis (MS) mouse model without inducing undesirable CB1-mediated side effects. These results support the interest in MAGL as a target for the treatment of MS.

Reactions of 1-tert-Butyl-3-phenylaziridinone and α-Bromo-N-tert-butylphenylacetamide with Benzyl-Grignard Reagents

1-tert-Butyl-3-phenylaziridinone (1) reacts with benzyl halide Grignard reagents (Br and Cl) to give N-tert-butyl-2,3-diphenylpropanamide (4), N-tert-butyl-2-phenylacetamide (3), N-tert-butyl-2-o-tolyl-2-phenylacetamide (5), 1-(tert-butylamino)-1,3-diphenylpropan-2-one (7), N-benzyl-N-tert-butyl-2-phenylacetamide (6), and N-tert-butyl-2-halo-2-phenylacetamide (2, X = Br, Cl).The choice of solvent appears to determine the relative amounts of products 4 and 5.The bromo amide 2 reacts with the Grignard reagent to give 3, 4, 5, 6, and 7 and may be involved to some extentin the reaction of 1 with benzyl-Grignard reagents.The formation of 5 represents anew type of "abnormal" product from a reaction of the benzyl-Grignard reagent; however, this product appears to fit well into the mechanistic pattern established for prior examples.